CO13: Infectious Diseases, Microbiology and Clinical Immunology

More infoTeamProjectsPublications
CO13: Infectious Diseases, Microbiology and Clinical ImmunologyClínica
Principal investigator
  • José Antonio Girón González
  • e-mail: joseantonio.giron@uca.es
  • ORCID: 0000-0002-7482-5828
Co-principal investigator
  • Manuel Antonio Rodríguez Iglesias
  • e-mail: manuel.rodrigueziglesias@uca.es
  • ORCID:
Lines of research
  1. HIV INFECTION: Modulation of immune function (dendritic cells, polymorphonuclears, macrophages, T lymphocytes) in HIV-infected patients: Alteration of the intestinal barrier/bacterial translocation. HCV coinfection.
  2. IHUMAN BACTERIAL INFECTIONS: Clinical setting. Prognostic factors. Biomarkers.
  3. ANTIMICROBIAL RESISTANCE MECHANISMS: Phenotypic and molecular detection. Multi-resistant gram-negative bacteria. Molecular epidemiology. Antifungals.
  4. PROTEOMIC IDENTIFICATION BY MALDI-TOF-MS: Rapid identification techniques. Detection of antimicrobial toxins and hydrolytic enzymes.
  5. EMERGING ZOONOTIC INFECTIONS: Antimicrobial-resistant zoonotic bacteria. Epidemiology of Arbovirosis.
  6. MARINE BACTERIA: Human infections by marine bacteria. Ecology and environmental factors.
  7. INFLAMMATORY AND IMMUNE DISORDERS IN SYSTEMIC AND ORGAN-SPECIFIC AUTOIMMUNE DISEASES: Inflammatory response in collagenosis, vasculitis and organ-specific autoimmune diseases. Modulation of immune function after treatment.
Key words
HIV HCV Inflammation Immunity Sepsis Bacterial resistance Collagenosis Vasculitis
Principal investigator
José Antonio Girón González
  • University Professor. Director of the Department of Internal Medicine
  • e-mail: manuel.rodrigueziglesias@uca.es
  • ORCID: 0000-0002-7482-5828
  • Research ID: M-2712-2015
  • Scopus ID: 10341314400
Co-principal investigator
Manuel Antonio Rodríguez Iglesias
  • University tenured professor, Director of the Department of Microbiology.
  • e-mail: manuel.rodrigueziglesias@uca.es
  • ORCID:
Team members
  • Ana Arizcorreta Yarza (Collaborating researcher)
  • Francisco Javier Casas Ciria (Collaborating researcher)
  • Sara Cuesta Sancho (Postdoctoral researcher)
  • Clotilde Fernández Gutiérrez del Álamo (Collaborating researcher)
  • Carolina Freyre Carrillo (Collaborating researcher)
  • Fátima Galán Sánchez (Collaborating researcher)
  • José Antonio Girón González (Principal Investigator)
  • Francisca María Guerrero Sánchez (Collaborating researcher)
  • Mercedes Márquez Coello (Technician)
  • Andrés Martín Aspas (Collaborating researcher)
  • Monserrat Montes de Oca Arjona (Collaborating researcher)
  • Manuel Antonio Rodríguez Iglesias (Principal Investigator)
  • María José Soto Cárdenas (Collaborating researcher)
National Funding Calls
  1. Instituto Nacional de Salud Carlos III, Strategic Action in Health 2017-2020. 2019. PI19/01361. Principal Investigator: José A. Girón González. HIV infection, NETs production and atherosclerosis.
  2. Instituto Nacional de Salud Carlos III, Strategic Action in Health. 2014. PI14/01779. Principal Investigator: José A. Girón González. Role of bacterial translocation in numerical and functional modifications of neutrophil polymorphonuclears in HIV-infected patients.
Regional Funding Calls
  1. Regional integration initiative (ITI) 2014-2020 for the province of Cadiz, by the Department of Health of the Junta de Andalucia and the European Regional Development Fund. PI-0076-2017. Principal Investigator: José A. Girón González. Effect of the composition of the intestinal microbiota on bacterial translocation and inflammatory and immune activation in HIV-infected patients: Modulation by MicroRNAs.
  2. Department of Health and Family of the Junta de Andalucia. PI0128-2018. Principal Investigator: Mercedes Márquez Coello. Analysis of the microRNA expression involved in immune modulation in HIV-infected patients.
Publications
  • Márquez Coello, Mercedes ;Montes de Oca Arjona, Monserrat ;Martín Aspas, Andrés ;Guerrero Sánchez, Francisca ;Fernández Gutiérrez del Álamo, Clotilde ;Girón González, José Antonio Antiretroviral therapy partially improves the abnormalities of dendritic cells and lymphoid and myeloid regulatory populations in recently infected HIV patients Scientific reports (en prensa) FI: 4.011 Q1
  • González Oria, María Carmen ;Márquez Coello, Mercedes ;Girón Ortega, José Antonio ;Argente Alcaraz, Joaquín ;Moya Molina, Miguel ;Giron Gonzalez, Jose Antonio Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects Journal of Neuroimmune Pharmacology (en prensa) FI: 3.870 Q1
  • Gutiérrez Saborido, Daniel ;Gutiérrez Valencia, Alicia ;González Domenech, Carmen María ;Löpez Ruz, Miguel Ängel ;Raffo Márquez, Miguel ;Omar, Mohamed ;Girón González, José Antonio. Incidence of lymphoma in HIV-HCV infected patients. Modifications in function of the anti-hepatitis C virus therapy Annals of Hematology 2019; 98: 1953-1959 FI: 2.850 Q3
  • Márquez-Coello M, Montes-de-Oca Arjona M, Fernández-Gutiérrez del Álamo C, Ruiz-Sánchez C, Girón-González JA. Peripheral Th17 cells expressing β7 intestinal homing receptor in recent and chronic HIV infections Clinical and Experimental Immunology 2018; 5: 350-60 FI: 3,711 Q2
  • Jiménez-Aguilar P, Romero-Palacios A, De la Calle IJ, Martínez-Rubio MC, Girón-González JA, Rodríguez-Baño J. Unsolicited consultation by infectious diseases specialist for patients with bloodstream infection: a prospective cohort study. Journal of Infection 2018; 5: 503-8 FI: 5,099 Q1
  • Martín-Aspas A, Guerrero F, García-Colchero F, Rodríguez-Roca S, Girón-González JA Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality Infection and Drug Resistance 2018;11:861-872 FI: 3,000 Q2
  • Arca-Suárez J, Galán-Sánchez F, Cano-Cano F, García-Santos G, Rodríguez-Iglesias MA. Antimicrobial susceptibility and molecular typing of toxigenic clinical isolates of Clostridium difficile causing infections in the south of Spain. Anaerobe. 2018; 54: 146-50 FI: 2,742 Q2
  • Flores-Chávez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Massó C, Rascón FJ, Pérez-Alvarez R, Zamora-Pasadas M, García-Pérez A, Lopez-Dupla M, Duarte-Millán MÁ, Ripoll M, Fonseca-Aizpuru E, Guisado-Vasco P, Pinilla B, de-la-Red G, Chamorro AJ, Morcillo C, Fanlo P, Soto-Cárdenas MJ, Retamozo S, Ramos-Casals M, Brito-Zerón P; GEAS-SS SEMI Registry. Severe, life-threatening phenotype of primary Sjögren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018; 36 Suppl 112:121-129. FI: 3,201 Q2
  • Arca-Suárez J, Galán-Sánchez F, Del Prado Montoro C, Rodríguez-Iglesias MA. A modified ESBL Nordmann/Dortet/Poirel-based protocol to optimize early sepsis management. J Microbiol Methods. 2017; 139: 45-47. FI: 1,701 Q3
  • Treviño A, Aguilera A, Rodríguez-Iglesias MA, Hernandez A, Benito R, Roc L, Ramos JM, Ortíz de Lejarazu R, Poveda E, Rodríguez C, Del Romero J, Calderon E, García J, Requena S, Soriano V, de Mendoza C. HTLV infection in HCV-antibody positive patients in Spain. AIDS Res Hum Retroviruses 2017; 33: 1013-7 FI: 1,935 Q3
  • Alonso-Ojembarrena A, Marín-Lozano ÁC, Galán-Sánchez F, Rodríguez-Iglesias MA. Etiología y frecuencia de factores de riesgo de sepsis tardía en una unidad de cuidados intensivos neonatales de nivel IIIb. Enferm Infecc Microbiol Clin. 2018; 36: 144-145 FI: 1,707 Q4
  • Arca-Suárez J, Galán-Sánchez F, Marin-Casanova P, Rodríguez-Iglesias MA. Direct identification of microorganisms from thioglycolate broth by MALDI-TOF MS. PLoS One. 2017; 12: e0185229. FI: 2,806 Q1
  • Ríos-Toro JJ, Márquez-Coello M, García-Álvarez JM, Martín-Aspas A, Rivera-Fernández R, Sáez de Benito A, Girón-González JA. Soluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock Plos One 2017; 12: e0175254 FI: 2,806 Q1
  • Rivero-Juarez A, Lopez-Cortes LF, Castaño M, Merino D, Marquez M, Mancebo M, Cuenca-Lopez F, Jimenez-Aguilar P, Lopez-Montesinos I, Lopez-Cardenas S, Collado A, Lopez-Ruz MA, Omar M, Tellez F, Perez-Stachowski X, Hernandez-Quero J, Girón-Gonzalez JA, Fernandez-Fuertes E, Rivero A, on behalf of the HERACLES cohort study team of the Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
  • Cristina Ginés; Sara Cuesta Sancho; Roman Kireev; Cruz García; Lisa Rancan; Sergio Damián Paredes; Elena Vara Ameigeiras; Jesús Ángel Fernández-Hernández Tresguerres. Protective effect of resveratrol against inflammation, oxidative stress and apoptosis in pancreas of aged SAMP8 mice. Experimental gerontology 2017; 90: 61 - 70. FI: 3,224 Q2
  • Sara Cuesta Sancho; SL Olson; So Eui Young; K Shimomura; Toru Ouchi; Fabián Preuss. Fibersol-2 induces apoptosis of Apc-deficient colorectal Cancer (SW480) cells and decreases polyp formation in Apc MIN mice. Cancer biology & therapy 2016; 17: 657 - 663. FI: 3,294 Q2
  • Márquez M, Fernández-Gutiérrez C, Girón-González JA Gut epithelial barrier dysfunction in HIV-HCV coinfected patients: Influence on innate and acquired immunity World J Gastroenterol 2016; 22: 1433-1448 FI: 3,055 Q2
  • Soto-Cárdenas MJ, Gandía M, Brito-Zerón P, Arias MT, Armiger N, Bové A, Bosch X, Retamozo S, Akasbi M, Pérez-De-Lis M, Gueitasi H, Kostov B, Pérez-Alvarez R, Siso-Almirall A, Lozano F, Ramos-Casals M. Etiopathogenic role of surfactant protein d in the clinical and immunological expression of primary Sjögren syndrome. J Rheumatol. 2015; 42: 111-8 FI: 3,236 Q2
  • Mira JA, Neukam K, López-Cortés LF, Rivero-Juárez A, Téllez F, Girón-González JA, de Los Santos-Gil I, Ojeda-Burgos G, Merino D, Ríos-Villegas MJ, Collado A, Torres-Cornejo A, Macías J, Rivero A, Pérez-Pérez M, Pineda JA. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. Eur J Clin Microbiol Infect Dis 2015; 34: 1879-84 FI: 2,857 Q2
  • Márquez M, Romero-Cores P, Montes-Oca M, Martín-Aspas A, Soto MJ, Guerrero F, Fernández-Gutiérrez C, Girón-González JA. Immune activation response in chronic HIV-infected patients: influence of hepatitis C virus coinfection Plos One 2015; 10: e0119568. FI: 3,234 Q1
  • So Eui Young; Mutsuko Ouchi; SL Olson; Sara Cuesta Sancho; D Reif; K Shimomura; Toru Ouchi. Tumor Suppression by Resistant Maltodextrin, Fibersol-2. Cancer Biology & Therapy 2015; 16: 460 – 465 FI: 2,921 Q2
  • Martin-Aspas A, Collado-Pérez C, Vela-Manzano L, Fernández-Gutiérrez del Alamo C, Tinoco-Racero I, Girón-González JA. Fiebre Q aguda: Riesgo de desarrollo de endocarditis Rev Clin Esp 2015; 215: 265-271 FI: 0,760 Q3
  • Del Toro MD, Nieto I, Guerrero F, Corzo J, Del Arco A, Palomino J, Nuño E, Lomas JM, Natera C, Fajardo JM, Delgado J, Torres-Tortosa M, Romero A, ¿Martín-Rico P, Muniain MA, Rodríguez-Baño J. Are hip hemiarthroplasty and total hiparthroplasty infections differententities? The importance of hip fractures. J; for the PJIG-SAEI/REIPI group. Eur J Clin Microbiol Infect Dis 2014; 33: 1439-48 FI: 2,668 Q2
  • Retamar P, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV, González-Galan V, Del Arco A, Pérez-Santos MJ, Téllez-Pérez F, Becerril-Carral B, Martín-Aspas A, Arroyo A, Pérez-Cortés S, Acosta F, Florez C, León-Ruiz L, Muñoz-Medina L, Rodríguez-Baño J; SAEI/SAMPAC/REIPI Bacteremia Group. Predictors of early mortality in very elderly patients with bacteremia: a prospective multicenter cohort. Int J Infect Dis. 2014; 26: 83-7. FI: 1,859 Q3
  • Corchado S, López-Cortés LF, Rivero-Juárez A, Torres-Cornejo A, Rivero A, Márquez-Coello M, Girón-González JA Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients. Plos One 2014; 9: e101760 FI: 3,234 Q1
  • López-Cortés LF, Viciana P, Girón-González JA, Vergara-Campos A, Márquez-Solero M, Martinez-Perez MA. Clinical and virological efficacy of Etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population. Plos One 2014; 9: e97262 FI: 3,234 Q1
  • Rivero-Juárez A, López-Cortes LF, Girón-González JA, Pineda JA, Rivero A. Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV. Lancet Infect Dis 2014; 14: 13-14 FI: 22,433 D1
  • Brito-Zerón P, Retamozo S, Akasbi M, Gandía M, Perez-De-Lis M, Soto-Cardenas MJ, Diaz-Lagares C, Kostov B, Bove A, Bosch X, Perez-Alvarez R, Siso A, Ramos-Casals M. Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. Lupus. 2014; 23: 166-75 FI: 2,197 Q3
  • T Brioche; R Kireev; S Cuesta; A Gratas-Delamarche; JAF Tresguerres; MC Gomez-Cabrera; J Viña. Growth Hormone Replacement Therapy Prevents Sarcopenia by a Dual Mechanism: Improvement of Protein Balance and of Antioxidant Defenses. The journals of gerontology. Series A, Biological sciences and medical sciences. 2014; 69: 1186-98. FI: 5,416 Q1, D1